Pfizer reported lower 3rd quarter profits on Tuesday, October 27, as COVID-19 dented demand for some medicines from patients whose regular healthcare patterns were disrupted.
The company saw an 11% drop in its hospital business in emerging markets, primarily due to fewer elective surgeries in China and shorter in-patient hospital stays in the country.